Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Novacyt ( (FR:ALNOV) ) has issued an update.
Novacyt S.A. announced the conclusion of legal proceedings involving its non-trading subsidiary, Lab 21 Healthcare Ltd, which faced health and safety charges related to the use of biological agents at its Axminster site. Lab 21 pleaded guilty and was fined £52,000, a sum that will not materially affect Novacyt’s financial position. This resolution marks the end of the case, with no further legal action anticipated, thus allowing Novacyt to continue focusing on its core business operations without additional liabilities from this matter.
More about Novacyt
Novacyt is an international molecular diagnostics company that offers a broad portfolio of integrated technologies and services with a focus on genomic medicine. The company develops, manufactures, and commercializes molecular assays and instrumentation, providing solutions across sectors such as human health, animal health, and environmental. Novacyt operates through three business segments: Clinical, Instrumentation, and Research Use Only, and is headquartered in Le Vésinet, France, with offices in the UK, Singapore, the US, and Canada.
See more data about ALNOV stock on TipRanks’ Stock Analysis page.